ArticleNature2025
In vivo screen of Plasmodium targets for mosquito-based malaria control.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Dynamics modelling and control strategies of malaria transmission interruption by antimalarial-treated nets.Infectious Disease Modelling · 2027Article
- New thinking for the next generation of antimalarials.EMBO molecular medicine · 2026Review
- PfApiAT2 is a proline transporter essential for the transmission of Plasmodium falciparum by the mosquito vector.Nature communications · 2026Article
- Anti-malarial contact dependent blocking of transmission of Plasmodium vivax by Anopheles darlingi mosquito vector.PLoS pathogens · 2026Article
- Identification of UCB-9721 as a potent inhibitor of MyoA, the essential class XIV myosin motor of apicomplexan parasites.bioRxiv : the preprint server for biology · 2026Article
- Demystifying Plasmodium development within the Anopheles mosquito.Current opinion in microbiology · 2026Review
- Ruthenium Complexes of Atovaquone Acting on Multiple Stages of theJournal of medicinal chemistry · 2026Article
- Potent acridone antimalarial against all three life stages of Plasmodium.Nature communications · 2026Article
- PfApiAT2 is a proline transporter essential for the transmission ofResearch square · 2026Article
- PfApiAT2 is a proline transporter essential for the transmission ofbioRxiv : the preprint server for biology · 2026Article
- Article
- MappingbioRxiv : the preprint server for biology · 2025Article
- Targeting Mitochondrial Function inInternational journal of molecular sciences · 2025Review
- Identifying antimalarials that disrupt malaria parasite transmission when fed to the mosquito.International journal for parasitology · 2025Article
- OocystMeter, a machine-learning algorithm to count and measurebioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Alexandra S Probst *Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0001-8389-8159
Douglas G Paton *Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Federico AppetecchiaDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Selina BoppDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0002-9412-9766
Kelsey L AdamsDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0002-1184-8360
Tasneem A RinveeDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Sovitj PouVA Medical Center, Portland, OR, USA.
Rolf WinterVA Medical Center, Portland, OR, USA.
Esrah W DuDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Sabrina YahiyaDepartment of Life Sciences, Imperial College London, London, UK.ORCID 0000-0003-1600-6186
Charles VidoudezHarvard Center for Mass Spectrometry, Cambridge, MA, USA.ORCID 0000-0003-0953-7800
Naresh SinghDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Janneth RodriguesGlobal Health Medicines R&D, GlaxoSmithKline, Madrid, Spain.ORCID 0000-0001-9693-1958
Pablo Castañeda-CasadoGlobal Health Medicines R&D, GlaxoSmithKline, Madrid, Spain.
Chiara TammaroDepartment of Chemistry and Pharmaceutical Technologies, Sapienza University of Rome, Rome, Italy.ORCID 0000-0003-1748-2512
Daisy ChenDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, USA.ORCID 0000-0001-6516-7029
Karla P Godinez-MaciasDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, USA.
Jasmine L JaramilloSouthwest Research Institute, San Antonio, TX, USA.
Giovanna PoceDepartment of Chemistry and Pharmaceutical Technologies, Sapienza University of Rome, Rome, Italy.ORCID 0000-0001-7466-8861
Michael J RubalSouthwest Research Institute, San Antonio, TX, USA.
Aaron NilsenVA Medical Center, Portland, OR, USA.
Elizabeth A WinzelerDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, USA.
Jake BaumDepartment of Life Sciences, Imperial College London, London, UK.ORCID 0000-0002-0275-352X
Jeremy N BurrowsMedicines for Malaria Venture, Geneva, Switzerland.ORCID 0000-0001-8448-6068
Michael K RiscoeVA Medical Center, Portland, OR, USA.ORCID 0000-0002-1343-5279
Dyann F WirthDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, USA. dfwirth@hsph.harvard.edu.ORCID 0000-0002-8604-4455
Flaminia CatterucciaDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, USA. fcatter@hsph.harvard.edu.ORCID 0000-0003-3295-6683
Funding
Optimizing ELQs for Treatment and Prevention of MalariaR01AI100569 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Michael Kevin RISCOE · 2014 to 2026
$8.0MThe Graduate Program in Tropical Infectious Diseases (GPiTID)T32AI049928 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI Flaminia Catteruccia, Phyllis J. Kanki · 2001 to 2026
$5.0MDetermining the interactions between mosquito oogenesis and Plasmodium falciparum survival and transmissionR01AI153404 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Flaminia Catteruccia · 2020 to 2026
$4.5MMalaria transmission blocking through mosquito contact with treated surfacesR01AI148646 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI CATTERUCCIA, FLAMINIA · 2020 to 2024
$3.6MDevelopment of a Sustained Release Injectable Formulation for Long-Term Delivery of ELQsR01AI141412 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI RISCOE, MICHAEL KEVIN · 2019 to 2022
$3.2MFrom bench to bednet: Developing novel mitochondrial inhibitors for killing Plasmodium in the malaria mosquitoR01AI179949 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Flaminia Catteruccia · 2024 to 2026
$2.1MIllumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
$600kBLRD VA I01 BX003312BLRD VA I01 BX005674BLRD VA IK6 BX004857NIAID NIH HHS R01 AI100569NIAID NIH HHS R01 AI141412NIAID NIH HHS R01 AI148646NIAID NIH HHS R01 AI153404NIAID NIH HHS R01 AI179949NIAID NIH HHS T32 AI049928NIH HHS S10 OD026929
Abstract
The decline in malaria deaths has recently stalled owing to several factors, including the widespread resistance of Anopheles vectors to the insecticides used in long-lasting insecticide-treated nets (LLINs)
Indexed as
AnophelesAntimalarialsMalariaMosquito ControlPlasmodium falciparumAnimalsDrug Evaluation, PreclinicalFemaleHumansInsecticide ResistanceInsecticidesInsecticide-Treated BednetsMalaria, FalciparumMiceMosquito VectorsQuinolonesAntimalarialsInsecticidesQuinolones
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.